Welcome back to the journal review. We're covering the November twenty twenty-six issue of Dermatologic Surgery this time, and I've got four pieces for you — a retrospective single-institution study on nerve-specific perineural invasion in high-risk squamous cell carcinoma, a review on an occupational hazard that doesn't get much airtime, a short letter responding to a systematic review on scar optimization, and a longer standalone review covering much of that same letter's territory in more depth. Let's get into it. First up is a retrospective cohort study out of Stanford, looking at the incidence of named-nerve perineural invasion in high-risk cutaneous squamous cell carcinoma treated with Mohs surgery. Quick framing of the gap here: we all know perineural invasion, or PNI, is a recognized risk factor for recurrence and metastasis in cutaneous squamous cell carcinoma, with reported incidence somewhere between two and a half and fourteen percent depending on the series. What's genuinely unknown is how often that PNI involves a specific, named nerve trunk rather than just small unnamed twigs — and that distinction matters a lot downstream, because radiation oncologists vary wildly in whether they extend the treatment field to cover the entire named cranial nerve pathway back toward the skull base. That's a real toxicity trade-off, and right now it's being made without good incidence data to guide it. So the authors did a twelve-year chart review, two thousand eleven through twenty twenty-two, at a single academic center, pulling every case staged at least Brigham and Women's Hospital T2a or higher that underwent Mohs surgery. They collected demographics, immunosuppression status, perioperative imaging when it was done, and tumor factors like differentiation, depth of invasion, and number of Mohs stages, then tracked recurrence and survival outcomes. This is a straightforward descriptive incidence study rather than a comparative one — there's no modeling or hypothesis testing here, just counting events in a defined population, and that's really the right tool for the job when your primary question is "how often does this rare, specific finding occur." A retrospective design also makes practical sense the authors don't spell out explicitly, but it's really the only way to accumulate enough high-stage tumors with PNI to say anything at all, since named-nerve involvement is uncommon enough that you'd need an impractically long prospective follow-up to capture a meaningful number of cases otherwise. Here's what they found. Of nearly a thousand cutaneous squamous cell carcinomas treated with Mohs surgery over that period, four hundred nine met the high-risk T2a-or-greater threshold, and of those, thirty-nine had histologic PNI on pathology. Just over half of that PNI group got perioperative cross-sectional imaging, either magnetic resonance imaging or CT. Six of the thirty-nine patients with histologic PNI — about fifteen percent of that subgroup — had named-nerve PNI identified on MRI. Every single one of those six tumors had invaded beyond the subcutaneous fat and was moderately or poorly differentiated. Four of the six went on to adjuvant radiation with varying field designs, three of them specifically targeting the nearest named nerve pathway. Outcomes in that treated group were mixed — one local recurrence, one nodal recurrence, and three patients with no recurrence at all — and radiation toxicity showed up as expected, with radiation dermatitis in three patients, altered taste in one, and radiation neuritis in one. The headline framing from the authors is worth sitting with: across the entire twelve-year high-risk cohort, named-nerve PNI was rare, under one percent if you assume none of the non-imaged cases were hiding it. But within the subset that already has histologic PNI, that fifteen percent figure is clinically meaningful, and they flag it may even be an underestimate, since narrowing to just the tumors that actually got MRI, the rate of named-nerve involvement climbs to about a quarter. The risk features clustering in that higher-risk group were deep invasion beyond fat, moderate-to-poor differentiation, larger size, and head and neck location — which lines up with prior literature suggesting MRI, not CT, is the better imaging choice here given its reported ninety-five percent sensitivity for detecting PNI. The honest limitation is the single-center tertiary-referral design, which likely enriches for more advanced, higher-stage disease and probably inflates both the PNI incidence and its severity relative to a general dermatology population, plus the numbers here are genuinely small — we're talking about six index cases driving the entire named-nerve conclusion. Practical takeaway: this isn't practice-changing in the sense of establishing a new universal imaging mandate, but it is a useful data point to sharpen your threshold. If you've got histologic PNI on a high-risk squamous cell carcinoma — especially head and neck, deep invasion past the fat, and poor differentiation — this supports reaching for MRI over CT when you're deciding on perioperative imaging, and it gives you something concrete to bring to a radiation oncology discussion about whether the treatment field really needs to chase the entire named nerve pathway or can stay more conservative. It's a call for individualized, imaging-informed field design rather than a blanket extended-field default. Second article is a review, not original research, covering a topic that honestly doesn't come up often in our continuing education: occupational risk of sexually transmitted infections for the dermatologic surgeon and aesthetic practitioner. The framing is patient-safety literature is everywhere, but exposure risk running the other direction — patient to physician — is comparatively neglected. The authors did a structured search across PubMed, Scopus, and Google Scholar, grading evidence using the Oxford Centre for Evidence-Based Medicine levels and GRADE strength-of-evidence terminology, which is a sensible move for a review trying to separate well-documented risks from theoretical ones rather than treating every case report with the same weight as a systematic review. The best-documented risk by far is human papillomavirus, transmitted through aerosolized surgical plume from lasers, electrocautery, and loop excision procedures. HPV DNA shows up consistently in plume samples, viable virus has been recovered as far as ten centimeters from the ablation site in lab models, and there are case reports of laryngeal papillomatosis and even oropharyngeal squamous cell carcinoma in laser surgeons — which is about as concrete a signal as you'll get from case-level evidence. Surveys also suggest more hand and nasal warts among dermatologists doing laser work. Bloodborne pathogens carry their own numbers worth knowing cold: HIV transmission risk is about three in a thousand for a percutaneous exposure and well under one in a thousand for mucous membrane exposure, and postexposure prophylaxis, started promptly, cuts that risk by roughly eighty percent. Hepatitis B is the standout worst actor among the bloodborne viruses in unvaccinated individuals — exposure to hepatitis B e-antigen-positive blood can infect somewhere between a fifth and a third of unvaccinated people percutaneously, and clinical hepatitis develops in up to about six in ten of those. Hepatitis C transmission risk per needlestick runs roughly half a percent to under two percent typically, though up to ten percent in higher-risk scenarios, and there's no vaccine, so sharps safety is the entire prevention strategy there. Herpes simplex rounds things out through direct contact with active lesions, including the old but still real risk of herpetic whitlow, and there are case reports of herpes encephalitis following filler injections, which is a reminder this isn't purely an HPV story. On prevention, the review lays out a fairly standard hierarchy of controls, but with some numbers that are worth remembering because they're actionable: smoke evacuation capture efficiency drops off steeply with distance, from about ninety-nine percent when the nozzle sits right at two to three centimeters from the treatment site down to about half that at seven to eight centimeters — so nozzle positioning isn't a minor technicality, it's the whole intervention. N95 or laser masks with HEPA filtration measurably reduce HPV DNA detection in the nasal mucosa compared with standard surgical masks, whose pore size is actually larger than fine plume particles. Double gloving cuts blood contact risk by roughly seventy percent. And hepatitis B vaccination remains the single most effective intervention available, given how survivable the virus is on dry surfaces and how high the transmission risk is without it. There's no original data here, so there's no limitations section to speak of — this is a synthesis piece. The practical takeaway, though, is genuinely actionable and probably overdue: confirm your own hepatitis B immunity status, use smoke evacuation properly positioned rather than just present in the room, upgrade respiratory protection for plume-heavy procedures, and have an actual postexposure protocol you can execute immediately rather than looking one up after the fact. Third is a short letter — a response to a prior systematic review on intraoperative scar optimization — proposing that postprocedural dyschromia deserves recognition as its own outcome measure rather than an afterthought. The authors' point is narrow and well-taken: existing scar optimization frameworks tend to focus on texture and contour, but in patients with darker skin, pigmentary change is often the dominant driver of how patients judge surgical success, and it's not explicitly captured in those frameworks. They cite a retrospective photographic review of eighty-three Mohs cases showing higher postinflammatory hyperpigmentation rates in Fitzpatrick skin types four and five, and point to surgeon-controllable variables: monofilament poliglecaprone twenty-five subcutaneous sutures outperforming braided polyglactin nine-ten, direct or local flap closure outperforming secondary intention or grafts, and staples for epidermal closure being the worst performer and best avoided in this population. They also flag that postoperative photoprotection needs to extend past ultraviolet coverage into long-wavelength UVA and visible light, since both are implicated in more persistent pigmentation in darker skin. Their ask is simple — build postprocedural dyschromia into future scar outcome studies as a core endpoint, ideally with objective colorimetry rather than subjective assessment. It's a brief, no-new-data commentary, but it's a legitimate nudge toward better outcome measurement in a population that's been underserved by the existing literature. Which brings us naturally to the fourth piece, a full review from Mayo Clinic covering essentially the same territory in much greater depth: postoperative dyschromia specifically in Fitzpatrick skin types four through six. This is a scoping-style literature review following PRISMA-ScR methodology, searching four databases from twenty fourteen through twenty twenty-five, and landing on nine included articles out of two hundred seventy-one initially identified — a useful reminder of just how thin the dedicated literature still is on this topic despite how common the complaint is in practice. Worth noting, the authors are explicit that they're trying to move away from blunt terms like "skin of color" toward more specific Fitzpatrick or Skin Color Ethnicity Scale categorization, and toward self-reported racial and ethnic background where the source studies allow it. The core clinical data point comes from an observational study they cite showing postinflammatory hyperpigmentation after Mohs surgery in just under half of patients with higher Fitzpatrick types, compared with under a fifth of patients with lower Fitzpatrick types — a difference that was both statistically significant and clearly clinically meaningful, not a trivial spread. Within that same study, postoperative complications were strongly associated with hyperpigmentation — about four out of five patients with a complication developed it, versus under a third without one — and repair type mattered enormously too: patients closed with grafts or allowed to heal by granulation developed hyperpigmentation at a markedly higher rate than those closed with direct linear repairs or flaps, something like eighty-some percent versus thirty percent. Both of those associations were statistically significant, and more importantly here, both are large enough gaps to actually change how you counsel and how you choose a repair when you have a choice. Suture selection data echoes the letter we just covered but with harder numbers: polyglactin nine-ten as a subcutaneous suture produced hyperpigmentation at nearly half-ish rates compared with under one in ten for poliglecaprone twenty-five in one analysis of linear repairs — again, statistically significant and a difference large enough to matter clinically, not just numerically. The mechanistic story offered is that more inflammatory suture material — braided over monofilament, absorbable over nonabsorbable, natural over synthetic — drives more postinflammatory pigment change, with natural absorbable materials like gut provoking the most reactive, neutrophil-heavy degradation response. Timely suture removal matters too; delayed removal of nonabsorbable suture risks what's called frustrated phagocytosis, where the inflammatory response escalates because immune cells can't fully clear the foreign material, and that drives more pigment change. One cited study on hand wounds found suture removal timing significantly associated with healing quality, with manual labor, tension-prone locations like palmar folds, older age, smoking, and skin-lightening product use all delaying ideal removal timing. There's also a smaller technique comparison suggesting running subcuticular closure scored better than running horizontal mattress on both patient and evaluator assessment, though the overall difference in total scar scores between the two didn't reach significance — a good example of a finding that's directionally interesting but not yet strong enough to mandate a technique change. On treatment of established hypopigmented scars, the review covers microdermal grafting — a melanocyte-keratinocyte suspension harvested from a donor site and applied to the depigmented area — with one small cohort showing roughly half the patients getting meaningful pigment improvement after a single session and up to ninety percent after three sessions, at the cost of a second surgical site and its own dyschromia risk. Topical prostaglandins and nonablative fractional lasers are mentioned as adjuncts, with nonablative preferred over ablative in darker skin types given lower hyperpigmentation risk, though the authors are honest that the evidence base for laser use specifically in these skin types remains thin. Since this is a literature synthesis rather than the authors' own comparative trial, there isn't a traditional methods-and-limitations arc to walk through beyond what I've covered — the limitation is really the state of the field itself, nine studies meeting criteria out of hundreds screened tells you this area is still underpowered and under-studied relative to how often it comes up in clinic. The practical takeaway, combining this review with the companion letter, is genuinely actionable at the chairside level and arguably practice-changing for anyone not already doing it: in Fitzpatrick four through six patients, favor monofilament synthetic absorbable suture like poliglecaprone twenty-five over braided or natural materials, favor direct or flap closure over grafts or secondary intention when the defect allows it, avoid staples, remove sutures promptly, counsel explicitly on broad-spectrum photoprotection that covers visible light and UVA and not just ultraviolet B, and set expectations up front that pigmentary change — separate from scar texture — is a likely and usually temporary part of healing in this population. That's the November issue — a nerve-specific imaging question in high-risk squamous cell carcinoma, an occupational hazard worth actually building a protocol around, and a two-part push to take pigmentary outcomes in darker skin as seriously as we take scar texture. Thanks for listening, and I'll see you next month.